Aditya Juloori (@ajuloorimd) 's Twitter Profile
Aditya Juloori

@ajuloorimd

Radiation Oncologist @UChicagoMed, Thoracic, Head/Neck

ID: 780064454247649280

calendar_today25-09-2016 15:20:33

495 Tweet

1,1K Followers

992 Following

Journal of Clinical Oncology (@jco_asco) 's Twitter Profile Photo

Rationale for Investigation of Neoadjuvant Chemoimmunotherapy Prior to Chemoradiation in Unresectable Stage III Non-Small Cell Lung Cancer: brnw.ch/21wRHpX Authored by Aditya Juloori et al. #NSCLC #lcsm

Sean Pitroda, M.D. (@seanpitroda) 's Twitter Profile Photo

We are grateful for the tremendous response to our recent manuscript and want to ensure a precise interpretation of our findings. Our research indicates that local radiation therapy in patients with pre-existing metastases may exert paradoxical effects—reducing the dissemination

Drew Moghanaki (@drewmoghanaki) 's Twitter Profile Photo

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. Thanks Millie Das MD for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy

Just when you thought the horizon for locally advanced NSCLC couldn’t get brighter… along comes HORIZON-01: ChemoRadiotherapy followed by Alectinib, Entrectinib, or Pralsetinib. 

Thanks <a href="/DasMillie11/">Millie Das MD</a> for the heads up. #ATS2025 #RadOncMeetsTargetedTherapy
Matthew McMillan, MD (@mattmcmillanmd) 's Twitter Profile Photo

Key nuance from this paper: Radiotherapy significantly REDUCED the seeding of **NEW** metastases, but it triggers a local wound-healing response that can promote growth of **EXISTING** metastases. The authors elegantly showed that this resistance mechanism to RT is targetable

University of Chicago Radiation Oncology (@uchicagoradonc) 's Twitter Profile Photo

UChicago is recruiting for a faculty radiation oncologist position. We'll be meeting candidates at ASTRO 2025. Check out our posting: careers.astro.org/jobs/view/facu… #radonc #ASTRO

Udhayvir Grewal (@ugrewalmd) 's Twitter Profile Photo

Excited to share our new commentary in Journal of Clinical Oncology (my first one) ASCO 🚨 In this patient-centered piece, we discuss the emerging case for organ preservation in select patients with locally advanced esophageal/GEJ cancer achieving a complete clinical response (cCR). Inspired by

Excited to share our new commentary in <a href="/JCO_ASCO/">Journal of Clinical Oncology</a> (my first one) <a href="/ASCO/">ASCO</a> 🚨

In this patient-centered piece, we discuss the emerging case for organ preservation in select patients with locally advanced esophageal/GEJ cancer achieving a complete clinical response (cCR). Inspired by
Rohan Katipally (@rohankatipally) 's Twitter Profile Photo

Proud of superstar resident, Dr. Abed Kawakibi Abed Rahman Kawakibi, MD, presenting how ctDNA may improve surveillance of HPV+ oropharyngeal cancer after chemoradiation at ASTRO — work emerging from treatment de-escalation protocols at our UChicago Head & Neck Cancer Program!

Proud of superstar resident, Dr. Abed Kawakibi <a href="/AbedKawakibi/">Abed Rahman Kawakibi, MD</a>, presenting how ctDNA may improve surveillance of HPV+ oropharyngeal cancer after chemoradiation at <a href="/ASTRO_org/">ASTRO</a> — work emerging from treatment de-escalation protocols at our UChicago Head &amp; Neck Cancer Program!
David Sher (@davidshermd) 's Twitter Profile Photo

I think we need to reserve judgement and final analysis until seeing all of the papers from these trials…. … but are these results really so different? - In the US trial, more IMRT patients (40% vs. 27% = 13% difference) received g-tubes. - In the UK trial, more IMRT patients